Shares for the Cure: Simplify Introduces Health Care ETF Benefiting Susan G. Komen

The Simplify Health Care ETF, trading under the symbol PINK, will donate all net profits from managing the fund on an annual basis to Susan G. Komen, the world’s leading breast cancer organization

New ETF is actively managed by renowned hedge fund manager Michael Taylor, who brings more than two decades of healthcare and biotech investing experience

NEW YORK--(BUSINESS WIRE)--Simplify Asset Management (“Simplify”), an innovative provider of Exchange Traded Funds (“ETFs”), today announced the launch of the Simplify Health Care ETF (PINK), the first ETF committed to donating all of its net profits from managing the fund on an annual basis to Susan G. Komen®, the world’s leading breast cancer organization.

PINK will be actively managed by renowned hedge fund investor Michael Taylor, who has more than 20 years of direct experience investing in the healthcare and biotech spaces, and who brings a rigorous research approach, due diligence processes, and deep knowledge of these sectors to build and run PINK’s underlying portfolio.

“We’re very grateful for this tangible commitment by the Simplify team to create a long-term source of support for the important work we’re doing to save lives and pursue an end to breast cancer,” said Paula Schneider, Komen’s president and CEO. “While this fund is launching during National Breast Cancer Awareness Month, the commitment it makes shows a recognition of the year-round support this cause needs as we have an incredible set of challenges before us. Decades of progress in lowering breast cancer mortality rates are being jeopardized by screening delays and treatment disruptions caused by the ongoing pandemic, persistent racial disparities in access to care are becoming painfully obvious, and women are carrying a disproportionate burden of the massive job loss and childcare crises affecting our country. This commitment will help support our advocacy, breakthrough research and important patient support and care for those facing the disease today.”

“Breast cancer impacts one in eight women in the U.S. at some point in her lifetime. Funding research to find the cures is an incredible challenge that demands significant financial resources, which is why Simplify is very pleased to have Susan G. Komen as the beneficiary for PINK, a fund that we believe provides investors with a way to grow their portfolios while simultaneously supporting an incredibly worthy cause,” said Paul Kim, CFA, CEO and Co-Founder with Simplify.

“The healthcare and biotech sectors are in the midst of a period of incredible innovation, rising to meet not only the ongoing pandemic, but producing breakthrough research that could have significant implications in the fight against cancer,” added Mr. Taylor. “But identifying those companies best poised for potential outperformance requires deep research and an active management approach. I could not be more pleased to be working with the Simplify team on PINK, providing investors with an important new tool while supporting the crucial work of Susan G. Komen.”

PINK has an expense ratio of 0.50 percent and Simplify has committed to donating all net profits from management of the fund to Susan G. Komen on an annual basis in perpetuity.

ABOUT SIMPLIFY ASSET MANAGEMENT INC

Simplify Asset Management Inc. is a Registered Investment Adviser founded in 2020 to help advisors tackle the most pressing portfolio challenges with an innovative set of options-based strategies. By accounting for real-world investor needs and market behavior, along with the non-linear power of options, our strategies allow for the tailored portfolio outcomes for which clients are looking. For more information, visit www.simplify.us.

ABOUT SUSAN G. KOMEN

Susan G. Komen® is the world’s leading nonprofit breast cancer organization, working to save lives and end breast cancer forever. Komen has an unmatched, comprehensive 360-degree approach to fighting this disease across all fronts and supporting millions of people in the U.S. and in countries worldwide. We advocate for patients, drive research breakthroughs, improve access to high-quality care, offer direct patient support and empower people with trustworthy information. Founded by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzy’s life, Komen remains committed to supporting those affected by breast cancer today, while tirelessly searching for tomorrow’s cures. Visit komen.org or call 1-877 GO KOMEN. Connect with us on social at www.komen.org/social.

Susan G. Komen’s mission is to save lives by meeting the most critical needs in our communities and investing in breakthrough research to prevent and cure breast cancer.

Investors should carefully consider the investment objectives, risks, charges and expenses of Exchange Traded Funds (ETFs) before investing. To obtain an ETF's prospectus containing this and other important information, please call (855) 772-8488, or visit SimplifyETFs.com. Please read the prospectus carefully before you invest. An investment in the fund involves risk, including possible loss of principal. Past performance does not guarantee future results.

The fund is new and has a limited operating history.

The Fund focuses its investments in securities of biotechnology and the healthcare industry. Economic, legislative or regulatory developments may occur that significantly affect these industries and cause the Fund’s net asset value to fluctuate due to this concentration.

The biotechnology industry can be significantly affected by patent considerations, including the termination of patent protections for products, intense competition both domestically and internationally, rapid technological change and obsolescence, government regulation and expensive insurance costs due to the risk of product liability lawsuits.

In addition, the biotechnology industry is an emerging growth industry, and therefore biotechnology companies may be thinly capitalized have limited product lines, distribution channels, resources and more volatile than companies with greater capitalizations. Biotechnology companies must contend with high development costs, which may be exacerbated by the inability to raise prices to cover costs because of managed care pressure, government regulation or price controls. Companies in the pharmaceutical industry are heavily dependent on patent protection. The expiration of patents may adversely affect the profitability of the companies. Pharmaceutical companies are also subject to extensive litigation based liability and approval of the Food and Drug Administration, a process that can be long and costly. Expanding international operations may lead to risks resulting from differences between U.S. and foreign legal, political and economic systems, regulatory regimes and market practices.

The Fund’s focus on the healthcare sector may cause its value to fluctuate and be more susceptible to particular risks of the sector such as extensive government regulations, restrictions on government reimbursement for medical expenses, rising costs of medical products and services, pricing pressure, an increased emphasis on outpatient services, changes in the demand for medical products and services, a limited number of products, industry innovation, changes in technologies and other market developments.

Simplify ETFs are distributed by Foreside Financial Services, LLC.

MEDIA:
Patrick Phalon
MacMillan Communications
(212) 473-4442
patrick@macmillancom.com